Free tool
FAERS Monitor: Udenyca
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761039 or its brand name (Udenyca, Pegfilgrastim-Cbqv). Reports on generic versions are filed under their own applications.
Reports
1,434
Serious
291
20% of reports
Hospitalization
125
Death reported
130
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- device malfunction915
- no adverse event715
- product dose omission issue159
- death99
- accidental exposure to product39
- device failure38
- product label confusion36
- neutrophil count decreased30
- device leakage24
- bone pain21
- nausea20
- white blood cell count decreased19
- device issue17
- product quality issue17
- hospitalisation16
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 78 |
| 2020 | 119 |
| 2021 | 68 |
| 2022 | 55 |
| 2023 | 30 |
| 2024 | 272 |
| 2025 | 358 |
| 2026 | 454 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,725 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| device malfunctionSignal | 915 | 193.5 | 186.0 | 173,323 |
| product label confusionSignal | 36 | 91.2 | 66.0 | 3,102 |
| no adverse eventSignal | 715 | 58.1 | 55.2 | 40,260 |
| device failureSignal | 38 | 36.7 | 26.8 | 1,282 |
| neutrophil count decreasedSignal | 30 | 10.8 | 7.6 | 257 |
| device leakageSignal | 24 | 8.1 | 5.5 | 143 |
| product dose omission issueSignal | 159 | 7.9 | 6.9 | 970 |
| accidental exposure to productSignal | 39 | 5.6 | 4.1 | 142 |
| bone painSignal | 21 | 5.3 | 3.4 | 68 |
| device issueSignal | 17 | 2.8 | 1.7 | 18 |
| white blood cell count decreasedSignal | 19 | 2.6 | 1.6 | 17 |
| product quality issue | 17 | 1.8 | 1.1 | 6 |
| death | 99 | 1.7 | 1.4 | 28 |
| hospitalisation | 16 | 1.5 | 0.9 | 2 |
| nausea | 20 | 0.4 | 0.2 | 22 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.